• NorthStrive Biosciences, a PMGC Holdings unit, filed two U.S. patent applications for EL-22 and EL-32 to address microgravity-related muscle loss.
• Applications assigned Nos. 19/774,556 and 19/774,575, extending NorthStrive’s myostatin and activin A IP into long-duration spaceflight.
• Moves position preclinical assets as potential muscle-preservation platforms beyond obesity drug-related weight loss, adding a space health angle.
• NorthStrive has no agreements with NASA, other space agencies, or commercial space operators tied to these programs.
• EL-22 and EL-32 remain preclinical with no human evaluation for microgravity muscle loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608210930PRIMZONEFULLFEED9814031) on August 21, 2026, and is solely responsible for the information contained therein.